Aardvark Therapeutics (NASDAQ:AARD) Research Coverage Started at Bank of America

Bank of America assumed coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note published on Monday, MarketBeat.com reports. The firm issued a buy rating and a $22.00 target price on the stock.

A number of other research firms have also recently commented on AARD. Royal Bank of Canada initiated coverage on Aardvark Therapeutics in a research report on Monday. They set an “outperform” rating and a $21.00 price objective for the company. Cantor Fitzgerald assumed coverage on Aardvark Therapeutics in a research report on Monday. They set an “overweight” rating and a $50.00 price objective for the company.

Aardvark Therapeutics Price Performance

Aardvark Therapeutics stock opened at $10.14 on Monday. Aardvark Therapeutics has a 52 week low of $9.21 and a 52 week high of $19.58.

Insider Buying and Selling at Aardvark Therapeutics

In other news, CFO Nelson Sun acquired 10,000 shares of Aardvark Therapeutics stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $160,000.00. Following the purchase, the chief financial officer now directly owns 99,484 shares of the company’s stock, valued at approximately $1,591,744. This trade represents a 11.18 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Tien-Li Lee acquired 16,542 shares of Aardvark Therapeutics stock in a transaction dated Friday, February 14th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the purchase, the chief executive officer now directly owns 1,496,175 shares in the company, valued at approximately $23,938,800. This represents a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.